Corezetta announced Thursday that it has launched PBD intelligence, a system for exploring compound and sustained-release (SR) drugs using the Big Data provided by the Health Insurance Review and Assessment Service (HIRA).
PBD intelligence, which is an upgrade of the previous PBD direct system, provides two platforms. The platforms include a system that analyzes 100 million combined prescriptions to excavate new compound drugs and a system that finds new SR drugs based on the analysis of daily doses of tablets and capsules.
The combined drug discovery tool provides not only the names of the drugs but also the combination prescribed in detail so that companies can obtain firsthand knowledge on the specified amount. The system can also analyze combined prescription by drug name, which in turn will make it easier for companies to find a drug that received the most orders.
“For example, a search for atorvastatin or statin will immediately give the user a combined prescription analysis that includes the drugs,” the company said in a statement.
The excavation tool for SR drugs classifies its categories into the total number of pills taken in a day and provides an analysis of the number of dosing days, the prescribed amount and payment.
Compared with existing methods of finding new products that depend on journals or research papers the company’s system is superior regarding accuracy and excavation efficiency.
The company also explained that PBD intelligence had maximized user convenience, accessibility and readability by providing an interactive analysis screen rather than a simple result.
“The PBD intelligence system is provided through our cloud server and delivers real-time analysis results to users at a high-speed rate, regardless of the user's computer specifications,” Corezetta CEO Yi Hong-gi said. “Our customers, who have used the beta-version of PBD intelligence, showed high satisfaction after using the system.”
The company aims to continue its contribution to the bio healthcare industry, Yi added.
The company plans to provide the new service free of charge to existing PBD AOD members, who have a membership level above PLUS.
<© Korea Biomedical Review, All rights reserved.>